The interaction of T lymphocytes with tumor cells, a key step in the antitumor immune response, is suppressed by adenosine, a nucleoside produced at increased levels within the hypoxic tumor environment. We have explored the mechanism by which adenosine interferes with the lymphocyte:tumor cell interaction. 
INTRODUCTION
The ability of the immune system to recognize and interact with tumor cells is a prerequisite for successful host defence against cancer. Most human tumors are extensively infiltrated with mononuclear cells, providing evidence for an ongoing attempt by the immune system to eliminate tumor cells through cell-mediated antitumor mechanisms [1] . However, the gradual emergence of neoplastic tissue shows that immune recognition and killing are not fully effective. This is in part because the tumor environment suppresses antitumor responses in the infiltrating cell population [1, 2] . The depressed antitumor response is accompanied by deficiencies in the signaling pathways of T and NK cells [3, 4] .
Tumor-associated immunosuppression is mediated to a large extent by soluble factors [5] [6] [7] . In past studies we have found that the purine nucleoside adenosine can act as a tumor-derived immunosuppressant [8 -12] . Adenosine is of interest because solid tumors, by virtue of their abnormal vasculature, are often hypoxic [13] , leading to increased production of adenosine through activation of the 5Ј-nucleotidase pathway and inhibition of adenosine kinase [14, 15] . We have shown that adenosine inhibits the activation of T cells [9] , the adhesion of activated T cells to adenocarcinoma tumor targets [10] , effector cell degranulation [11] , and target cell lysis [12] . The levels of adenosine in the extracellular fluid of mouse and human carcinomas are high enough to be able to suppress these activities [8] .
In this paper we focus upon the role of adenosine in modulating T cell adhesion to tumor cells. We explore the cell adhesion molecule(s) that might be target(s) of adenosine modulation during the interaction of T cells with tumor target cells. Several candidates are present on the lymphocyte surface. These include integrins such as LFA-1 (␣ L ␤ 2 ), VLA-4 (␣ 4 ␤ 1 ), VLA-5 (␣ 5 ␤ 1 ), and LPAM-1 (␣ 4 ␤ 7 ) [16] . Of particular interest are the ␣ 4 integrins ␣ 4 ␤ 1 and ␣ 4 ␤ 7 , which are expressed on T cells, B cells, NK cells, and other leukocytes [17] [18] [19] [20] [21] [22] [23] . Integrin ␣ 4 ␤ 1 plays a role in T cell interactions in the thymus [24] , in secondary lymphoid organs [25] , and at mucosal sites [26] , while ␣ 4 ␤ 7 has a particular role in T cell migration into gut-associated lymphoid tissue [27, 28] . Both are important in T cell activation, proliferation, and apoptosis [17, 18, 29 -32] . In this paper we identify ␣ 4 ␤ 7 as the major cell adhesion molecule involved in the adhesion of T cells to syngeneic MCA-38 adenocarcinoma cells and show that it is subject to regulation by adenosine.
MATERIALS AND METHODS
Materials. MCA-38-LD (liver-derived) murine (C57 BL/6) colon adenocarcinoma cells were kindly provided by Dr. S. Gallinger (Samuel Lunenfeld Research Institute, Toronto, Ontario). Culture media and calf sera were from ICN-Flow (St-Laurent, Quebec), and culture vessels (Nunc) were from Gibco (Gaithersburg, MD). C57 BL/6 mice (6 -8 weeks old) were obtained from Charles River Canada (Lasalle, Quebec) and were maintained on standard laboratory chow with water ad libitum. Hamster anti-mouse mAb against the chain of the T cell CD3 complex (clone 145-2C11) was used in the form of culture supernatant from a hybridoma kindly provided by Dr. J. Bluestone (University of Chicago, Chicago, IL). Nylon wool was from Cellular Products (Buffalo, NY). Bacteriological-grade petri plates for lymphocyte panning were obtained from Fisher Scientific (Ottawa, Ontario). Adenosine was obtained from Sigma Chemical Co. (St Louis, MO). Coformycin, Gly-Arg-Gly-Asp-Asn-Pro (GRGDNP) peptide, Gly-Arg-Ala-Asp-Ser-Pro (GRADSP) peptide, and fibronectin were purchased from Calbiochem (San Diego, CA). High-specificactivity 3 H-labeled amino acid mixture (84 -147 Ci/mmol) was obtained from Amersham (Oakville, Ontario).
125 I-labeled sheep antimouse IgG, F(abЈ) 2 v / v heat-inactivated newborn calf serum. Stock cultures were passaged at confluence after release of the cells by trypsinization. Cultures for use in adhesion assays were seeded in 4-or 96-well plates 2 days prior to experiments, by which time they were at confluent density.
Preparation of anti-CD3-stimulated T cells. Lymphocytes were isolated from spleens, freed of contaminating red cells by brief hypotonic lysis, and enriched for T cells by passage through nylon wool as described [10] . The lymphocytes were activated by incubation with anti-CD3 mAb (1/20 -1/40 dilution) for 2 h while concurrently being labeled with 3-5 Ci/ml 3 H-labeled amino acids in amino-acidfree RPMI 1640 medium containing 1% fetal calf serum (FCS) [10] . Samples of the radiolabeled T cell suspension were measured for their radioactivity to allow subsequent calculation of cell numbers.
Assay of T cell adhesion to MCA-38 cells. Unless otherwise stated, drugs, antibodies, or control vehicle were added to the T cell suspension 5 min prior to the initiation of the adhesion assay. The assay was performed as previously described [10] using 1 ϫ 10 6 anti-CD3-stimulated T cells/well and MCA-38 cell monolayers in four-well plates. Coformycin (1 M) was included with adenosine (and in controls) in assays to prevent the breakdown of adenosine through adenosine deaminase. Previous work has shown that coformycin by itself has no significant effect on T cell adhesion to tumor cells [10] . Unless otherwise indicated, the concentrations/dilutions of mAbs used in adhesion assays were R1-2, 9C10, KMI6, and FIB27 at 1 g/ml, FD441.8 at 1/4, and BMA5 and MK2.7 at 1/10. Matched control mAbs were used at the same concentrations/dilutions. Treatment of the T cells with the antibodies had no effect on cell viability as assessed by the MTT dye reduction assay [33] or trypan blue exclusion (data not shown). Unless otherwise noted, all figures show representative sets of data taken from at least three independent experiments. Differences between treatment groups were evaluated using a two-tailed Student t test.
Assay of T cell adhesion to fibronectin or fibronectin-coated MCA-38 cells. To measure T cell adhesion to fibronectin-coated substrata, the adhesion assay [10] was modified for use with fibronectin-coated 96-well plates. Fibronectin was added to plates at a concentration of 10 g/ml and incubated for 2 h at 37°C, after which time the wells were washed with phosphate-buffered saline (PBS) and treated with 2% bovine serum albumin (BSA) to reduce nonspecific binding. Radiolabeled, anti-CD3-stimulated T cells (200 l, ϳ10 5 cells) were added to wells along with other additions with the plates kept on ice. The T cells were allowed to settle for 30 min at 4°C and the plate was then transferred to 37°C for 5 min to permit cell adhesion. Adherent T cells were enumerated as before [10] . Four to eight replicate determinations were made in each experiment.
Negative selection of lymphocytes using adsorbed anti-␣ 4 antibody (panning). Panning was carried out following the method of Wysocki and Sato [34] . Briefly, bacteriological-grade petri plates (15 ϫ 100 mm) were coated with goat anti-rat IgG at 10 g/ml in 0.05 M Tris, pH 9.5, at room temperature for 60 min and then washed three times with PBS. PBS with 5% FCS was added to the plates, which were then incubated for 60 min at room temperature. Anti-CD3-stimulated T cells (1 ϫ 10 6 /ml) were treated with 9C10 mAb against ␣ 4 integrin at 1 g/ml or control in RPMI medium with 20 mM Hepes and 1% BSA for 60 min at room temperature. Washed cells were added to the plates at 4°C and gently swirled every 15 min for 60 min. Nonadherent cells were removed from the plates, washed, and processed as required.
Flow cytofluorimetric analysis. Anti-CD3-stimulated T cells were washed and resuspended (10 6 cells) in filter-clarified PBS with 2.5% BSA and 0.2% sodium azide containing the primary mAb (1 g/10 6 cells), for 40 min at 4°C. The mAbs used were 9C10, KMI6, and FIB27. The cells were washed twice with the same buffer and then incubated with FITC-secondary mAb conjugate (1 g/10 6 cells) for 45 min at 4°C. After three further washes the cells were fixed in 1% paraformaldehyde and kept at 4°C until analyzed. Flow cytofluorimetric analysis was carried out with a FACScan (BD Immunocytometry Systems, Mountain View, CA) flow cytometer equipped with a 15-mW argon laser operating at a wavelength of 488 nm. The FACScan was interfaced with a Hewlett-Packard 300 computer, and the data collected in each assay were analyzed with Consort 30 software using Kolmogorov-Smirnoff statistics.
Binding assay of adhesion molecules on tumor cell monolayers. Monolayer cultures of MCA-38 cells in four-well plates were placed on ice, and all subsequent washes and incubations were carried out at 4°C. Wells were washed with 500 l PBS containing 0.2% BSA and then incubated with 175 l PBS containing 1% BSA and 1 g/ml primary antibody or isotype control. After incubation for 60 min at 4°C, the wells were washed twice as before and further incubated with 175 l PBS containing 1% BSA and 1.2 Ci/ml 125 I-labeled sheep anti-mouse IgG, F(abЈ) 2 fragment, for 60 min at 4°C. The monolayers were then washed three times and solubilized in 500 l of 0.5 M NaOH for 60 min at room temperature before the counting of the radioactivity.
RESULTS

Lack of Involvement of LFA-1 or VLA-5 in T Cell Adhesion to MCA-38 Cells
Stimulation of T cells with anti-CD3 mAb induces a non-MHC-restricted cytotoxic phenotype [35] , which allows the T cells to adhere with high avidity to syngeneic tumor cells, in this case the murine MCA-38 colon carcinoma cell line [10] . Since lymphocyte:tumor cell interaction frequently requires the adhesion of LFA-1 on lymphocytes to ICAM family ligands on the target cell [36] , we first asked whether LFA-1 played a major role in the adhesion of anti-CD3-stimulated T cells to MCA-38 cells. Surprisingly, mAb to LFA-1 completely failed to inhibit the adhesion of T cells to MCA-38 target cells, compared to a control mAb at the same dilution (adherent T cells ϫ 10 Ϫ3 : control, 101.1 Ϯ 2.3; anti-LFA-1, 109.6 Ϯ 2.0; mean Ϯ SE, n ϭ 4). The lack of inhibition of adhesion of T cells to MCA-38 cells by anti-LFA-1 mAb was not due to the inability of the mAb to block effector cell-target cell interactions, as the same antibody preparation at an identical dilution substantially inhibited killing of P815 mastocytoma target cells by anti-CD3-activated T cells (data not shown). The absence of inhibition by anti-LFA-1 was also not due to lack of expression of LFA-1 on the T cells. FACS analysis showed that at least 86% of T cells expressed significant levels of LFA-1 protein (data not shown). However, we were unable to detect ICAM-1, the principal ligand for LFA-1, on MCA-38 cells (data not shown). Thus, the LFA-1:ICAM-1 interaction does not play a role in the adhesion of T cells to MCA-38 cells.
We therefore considered alternative possibilities. Since colorectal carcinoma cells are known to secrete fibronectin which is deposited at the cell surface [37] , we questioned whether the T cells could be binding to fibronectin on MCA-38 cells through the classical fibronectin receptor VLA-5 (␣ 5 ␤ 1 ). This was excluded because (i) VLA-5 is not detectable on short-term-activated T cells by flow cytofluorimetry (data not shown), (ii) the RGD-containing hexapeptide GRGDNP did not inhibit T cell adhesion to MCA-38 cells, compared with the control peptide GRADSP (adherent T cells ϫ 10 Ϫ3 : GRGDNP, 113.9 Ϯ 3.3; GRADSP, 111.1 Ϯ 2.4; mean Ϯ SE, n ϭ 4), and (iii) a mAb against VLA-5 completely failed to inhibit the T cell:MCA-38 cell binding (adherent T cells ϫ 10 Ϫ3 : control, 156.0 Ϯ 7.3; anti-VLA-5, 157.1 Ϯ 11.2; mean Ϯ SE, n ϭ 4). This excludes VLA-5 as a major player in this interaction; binding through the alternative receptor VLA-4 (␣ 4 ␤ 1 ) is addressed below.
The Integrin ␣ 4 ␤ 7 Plays a Key Role in T Cell Adhesion to MCA-38 Cells
Anti-CD3-stimulated T cells express ␣ 4 , ␤ 1 , and ␤ 7 integrin subunits on their cell surface (Fig. 1) . Both ␣ 4 ␤ 1 (VLA-4) and ␣ 4 ␤ 7 (LPAM-1) are RGD-insensitive integrins involved in T cell adhesion and activation [16 -18, 29, 30] and have the potential to be involved in T cell adhesion to MCA-38 cells. A mAb (clone R1-2) to the ␣ 4 integrin subunit inhibited adhesion by 48% (Fig.  2a) , showing that ␣ 4 integrin(s) do indeed play a part in T cell adhesion to MCA-38 cells. Since the ␣ 4 integrin subunit may be associated with either ␤ 1 or ␤ 7 integrin subunits [16] , we next examined the effects of using antibodies against ␤ 1 or ␤ 7 on T cell binding to MCA-38 cells. Anti-␤ 1 mAb KMI6 had no effect on T cell adhesion to MCA-38 cells (Fig. 2b) . A second mAb against ␤ 1 , HM␤1-1, at concentrations from 0.2 to 5 g/ml, was also without effect on adhesion (data not shown). In contrast to the negative results for ␤ 1 , a mAb (FIB27) against the ␤ 7 subunit strongly inhibited binding (Fig.  2b ). This inhibition due to mAb against the ␤ 7 subunit was not altered by anti-␤ 1 (Fig. 2b) , pointing to ␣ 4 ␤ 7 as the major ␣ 4 integrin involved in the interaction of T cells with MCA-38 cells.
T Cell ␣ 4 ␤ 7 Binds to VCAM-1 on the MCA-38 Cells
If ␣ 4 ␤ 7 on T cells in indeed a major player in the interaction with MCA-38 cells, its counterpart on MCA-38 cells is likely to be either MAdCAM-1 or VCAM-1 or the tumor cell [16] . Figure 3 clearly shows that while MAdCAM-1 is absent from MCA-38 cells, VCAM-1 is expressed and present at the tumor cell surface. VCAM-1 can also be detected on trypsin-released MCA-38 cells by FACS analysis (A. K. Bennett and J. Blay, unpublished data). As shown in Fig. 4 , a mAb to VCAM-1 (MK2.7) substantially inhibited the binding of T cells to MCA-38 cells, confirming the view that VCAM-1 plays a role in the recognition by T cells.
We therefore believe that a key cell adhesion molecular interaction between T cells and syngeneic MCA-38 cells is between ␣ 4 ␤ 7 on the effector cell and VCAM-1 on the tumor target. 
Adenosine Acts by Modulating Adhesion through ␣ 4 ␤ 7
We have previously shown that the tumor product adenosine suppresses the T cell:MCA-38 cell interaction, by acting on specific A3 adenosine receptors on the T cells [10] . We therefore examined whether adenosine might function to suppress ␣ 4 ␤ 7 -mediated cell adhesion. For these experiments we blocked the ␣ 4 subunit more rigorously by combining a second anti-␣ 4 mAb (clone 9C10), which binds to a distinct epitope on the ␣ 4 subunit, with R1-2. Each antibody by itself maximally inhibited binding of T cells to MCA-38 cells at a concentration of ϳ1 g/ml (Fig. 5a) . The inhibitory effect of the two antibodies when combined at this concentration (73%) was markedly greater than that of either R1-2 (47%) or 9C10 (53%) alone (Fig. 5b) .
To examine whether adenosine inhibited T cell adhesion to MCA-38 cells through ␣ 4 ␤ 7 , we used three distinct approaches. First, we pretreated the T cells for 2 h with adenosine (10 M) prior to measuring ␣ 4 -mediated cell adhesion. The treated T cells were washed free of adenosine and their adhesion to MCA-38 cells was then studied in the absence or presence of anti-␣ 4 mAbs (both R1-2 and 9C10). The magnitude of the adenosine effect (20% inhibition) was somewhat less with adenosine having been washed out prior to the assay ( Fig. 6a ; compare Ref. 10 ), but the inhibition of T cell adhesion due to adenosine was reproducibly observed in the control situation. The adhesion of T cells to MCA-38 cells as expected was markedly (75%) inhibited by the combination of R1-2 and 9C10 anti-␣ 4 mAbs, and in the presence of these anti-␣ 4 mAbs adenosine consistently failed to inhibit T cell adhesion (Fig. 6a) , providing the first evidence that the effect of adenosine is on ␣ 4 -mediated cell adhesion. Second, in a different approach, we first exposed the T cells for 30 min to the anti-␣ 4 mAbs to block ␣ 4 ␤ 7 and then studied adhesion with adenosine absent or present in the assay (Fig. 6b) . Adenosine again inhibited adhesion in untreated cells but once more the inhibition was completely eliminated in cells that had been blocked with anti-␣ 4 mAbs (Fig. 6b) . This provides further evidence that the effect of adenosine is on ␣ 4 -mediated cell adhesion. Third, to show more directly that adenosine was acting through the ␣ 4 integrin, we depleted the anti-CD3-stimulated T cell population of ␣ 4 ϩ cells by panning [34] to determine whether the adenosine inhibition of adhesion to MCA-38 cells would be eliminated. The ␣ 4 -depleted T cells (enriched and added at the same cell concentration) adhered to MCA-38 cells, demonstrating that T cells do not depend solely on ␣ 4 ␤ 7 for adhesion. However, unlike control cells the ␣ 4 Ϫ cells were completely unresponsive to adenosine in terms of inhibition of binding to MCA-38 cells (Fig. 7) . Together with the data in Fig. 6 , the results from these panning experiments argue strongly that the adenosine inhibition of T cell adhesion to MCA-38 cells is mediated through the ␣ 4 integrin.
Adenosine Does Not Suppress T Cell Binding to
Fibronectin through ␣ 4 ␤ 1
Our data pointed strongly to adenosine modulation of T cell adhesion to MCA-38 cells through ␣ 4 ␤ 7 on the T cells, on which adenosine acts [10] . However, it remained possible that adenosine might have effects through ␣ 4 ␤ 1 in situations where the latter ␣ 4 integrin is the major participant in adhesion. We therefore considered whether adenosine might inhibit T cell binding to fibronectin, which occurs preferentially through ␣ 4 ␤ 1 (VLA-4) in cells expressing both ␣ 4 integrin subtypes [38] . As expected, T cells bound to purified fibronectin (Fig. 8a) ; adhesion of T cells to fibronectin-coated plates ranged from 23 to 32% of total T cells and was at least threefold greater than binding to BSA-coated plates alone. This binding is not through the classical fibronectin receptor VLA-5 (␣ 5 ␤ 1 ) because (i) as indicated above, T cells briefly activated with anti-CD3 mAb by our protocol do not express significant levels of VLA-5 and (ii) binding to fibronectin was insensitive to inhibition by RGD (Arg-Gly-Asp)-containing peptide (data not shown). However, the binding of T cells to fibronectin was markedly inhibited by the combination of anti-␣ 4 antibodies R1-2 and 9C10 (Fig. 8b) , consistent with the view that T cells can bind to fibronectin through the alternative receptor ␣ 4 ␤ 1 .
Although T cells bound to fibronectin in an ␣ 4 ␤ 1 -dependent manner, this binding was not regulated by adenosine. Adenosine failed to inhibit binding of T cells to fibronectin-coated plates (Fig. 9a) . This was not due to the shorter time chosen for optimal T cell binding to plastic-adsorbed fibronectin (5 min) compared with the greater time (60 min) in our standard assay of binding to MCA-38 cell monolayers because adenosine also significantly reduced T cell binding to MCA-38 cells in a shortened (5 min) cell adhesion assay (Fig. 9b) monolayers with fibronectin (10 g/ml, 2 h, 37°C) drastically reduced the adenosine-induced inhibition of T cell binding to these cells (Fig. 9b ). This agrees with the suggestion that adenosine is not able to affect ␣ 4 ␤ 1 -mediated binding to extracellular matrix, even in a cellular context, but inhibits the ␣ 4 ␤ 7 -mediated adhesion to cellular VCAM-1.
DISCUSSION
We examined the key adhesion molecules that might participate in the binding of anti-CD3-stimulated T lymphocytes to syngeneic colon adenocarcinoma target cells and sought an explanation for the adenosinemediated inhibition of adhesion. The LFA-1/ICAM in- 
FIG. 8.
T cell adhesion to fibronectin through ␣ 4 ␤ 1 . (a) T cells were incubated on wells coated with BSA (2% w/v) or fibronectin (10 g/ml) and allowed to settle for 30 min at 4°C, and adherence was then measured after 5 min at 37°C. Each bar represents mean Ϯ SE (n ϭ 8). **Significantly greater; P Ͻ 0.01. (b) T cells were added to fibronectin-coated wells in the presence of control mAb (2 g/ml; clear bar) or anti-␣ 4 mAbs (R1-2 and 9C10 each at 1 g/ml; hatched bar) and adhesion was measured after 5 min at 37°C. Each bar represents mean Ϯ SE (n ϭ 4). **Significant inhibition; P Ͻ 0.01.
teraction is key to the lysis of many malignant cells by cytotoxic immune effector cells [36, 39] . However, a mAb to LFA-1 did not inhibit the adhesion of T cells to MCA-38 cells, even though (i) LFA-1 was highly expressed on T cells, (ii) the anti-LFA-1 mAb was functional in terms of blocking T interactions with P815 mastocytoma targets, and (iii) a concentration of anti-LFA-1 mAb similar to that used in these experiments has been shown to inhibit killing of appropriate tumor targets by NK cells, cytotoxic T lymphocytes, and LAK cells [39] . The lack of effect of anti-LFA-1 mAb in this system is likely due to the absence of a suitable counterligand(s) on the MCA-38 cells.
Colorectal carcinoma cells can secrete fibronectin, which is deposited at the cell surface [37] . Therefore, we needed to consider whether VLA-5 (␣ 5 ␤ 1 ), the classical fibronectin receptor, might mediate T cell binding to MCA-38 cells. However, we were unable to show significant levels of VLA-5 on the surface of these short-term (2 h)-activated T cells; and neither RGD peptide nor anti-VLA-5 mAb were able to block binding. Our data therefore rule out binding to cell-surface fibronectin through VLA-5.
In contrast to the above findings, T cell binding to MCA-38 cells was significantly inhibited by antibodies directed against the ␣ 4 integrin subunit. Our findings are reminiscent of data obtained in studies of LFA-1-deficient mice, in which ␣ 4 integrins have been shown to compensate for the lack of LFA-1/ICAM interactions [40] . The inhibition of T cell:MCA-38 cell binding was most marked when two anti-␣ 4 mAbs that have specificity for distinct ␣ 4 epitopes, R1-2 and 9C10, were used in combination. The enhanced effect of this combination is consistent with results reported elsewhere [41] .
We initially assumed that the ␣ 4 integrin involved in T cell binding to MCA-38 cells was ␣ 4 ␤ 1 (VLA-4), because antibody R1-2 had been reported to be specific for VLA-4 and is reported to bind negligibly to ␣ 4 ␤ 7 at the concentrations that we found maximally inhibited T cell binding to MCA-38 cells [42] [43] [44] . However, we were subsequently unable to demonstrate the involvement of ␣ 4 ␤ 1 , even though (i) we confirmed the presence of the ␤ 1 subunit on the T cells and (ii) the T cells bind to fibronectin through ␣ 4 ␤ 1 as expected. Instead, we found significant inhibition of adhesion with anti-␤ 7 (Fig. 2b) . While ␣ 4 ␤ 7 is mainly associated with lymphocytes trafficking to the gut-associated lymphoid tissue [27, 28] , a proportion of both CD4 ϩ and CD8 ϩ T cells in mouse spleen express ␣ 4 ␤ 7 [19] . Our evidence argues that the ␣ 4 integrin involved in T cell binding to MCA-38 cells is ␣ 4 ␤ 7 . Its counterpart on the MCA-38 tumor cells appears to be VCAM-1. VCAM-1 is a ligand for the binding of ␣ 4 ␤ 7 , as an alternative to the preferred ligand MAdCAM-1 [16, 23, 45] . We confirmed by both radioantibody binding assay and flow cytofluorimetry that VCAM-1 is present on the surface of our MCA-38 cells, whereas MAdCAM-1 is not. While VCAM-1 is usually thought of as an endothelial and stromal cell adhesion molecule, it is present on certain neoplasms such as gliomas [46] , mesotheliomas [47] , melanomas [48] , and lymphomas [49] , and on leukemic cells of B cell and myeloid origin [50] . Interactions between ␣ 4 ␤ 7 and VCAM-1 (on endothelial cells) are also important in the adhesion of T cells in the context of inflammation [51] .
The binding of T cells to VCAM-1 through ␣ 4 ␤ 7 and not ␣ 4 ␤ 1 despite the presence of ␣ 4 ␤ 1 on the T cell surface was unexpected. However, the binding characteristics of ␣ 4 ␤ 1 and ␣ 4 ␤ 7 for the VCAM-1 molecule are not identical [52] and differ in their activation requirements, with adhesion of ␣ 4 ␤ 7 to domain 4 of VCAM-1 requiring significantly lower levels of activation [53] . A switch between ␣ 4 ␤ 1 and ␣ 4 ␤ 7 in preference for binding to VCAM-1 occurs in human eosinophils depending on the cellular activation state [23] . A similar phenomenon may explain the unexpected selectivity of ␣ 4 ␤ 7 for VCAM-1 binding in our cellular model, in which the T cells are at an early stage of activation.
Having established that the major interaction of T cells with MCA-38 cells was between ␣ 4 ␤ 7 on the effector cell and VCAM-1 on the target, we considered the possibility that the ␣ 4 ␤ 7 /VCAM-1 interaction might be modulated by adenosine. Adenosine markedly inhibits T binding to MCA-38 cells through a receptor-mediated mechanism operating at the level of the T cell [10] . We used three approaches to test whether the inhibition of T cell binding to MCA-38 cells by adenosine depended upon the participation of ␣ 4 ␤ 7 . We found that (i) adenosine treatment fails to inhibit adhesion in T cells when anti-␣ 4 antibodies are present, (ii) preincubation with anti-␣ 4 mAbs abrogates the subsequent inhibition of adhesion due to adenosine, and (iii) the adhesion of ␣ 4 Ϫ cells is not suppressed by adenosine. In all three approaches, adenosine consistently failed to inhibit T cell binding to MCA-38 cells when ␣ 4 integrin was absent or functionally blocked. We therefore conclude that adenosine modulates ␣ 4 ␤ 7 on T cells to reduce its binding to VCAM-1 on the MCA-38 carcinoma cells and that adenosine partially inhibits the interaction of T lymphocytes with tumor cells by blocking the function of integrin ␣ 4 ␤ 7 .
Surprisingly, adenosine had no effect on the ␣ 4 ␤ 1 -mediated binding to fibronectin, whether the latter was presented on a plastic substratum or deposited on a cell monolayer. This was not an outcome of the differences in assay conditions, since adenosine inhibited T cell binding to MCA-38 cells in a shortened assay, comparable to the fibronectin binding assay. The ability of adenosine to inhibit ␣ 4 ␤ 7 binding to VCAM-1, but not ␣ 4 ␤ 1 binding to fibronectin, may give clues as to the change(s) that occur in the integrin complex in response to adenosine.
We do not yet know how adenosine modulates ␣ 4 ␤ 7 function. Its effect on T cell:MCA-38 cell binding is exerted rapidly, within 5 min at 37°C (Fig. 9b) , and is persistent in that it is seen when cells are pretreated with adenosine, thoroughly washed, and subsequently assayed over a 60-min time period (e.g., Fig. 6a ; and Ref. 10 ). There is no apparent downregulation of ␣ 4 ␤ 7 protein over the course of the assay, as flow cytofluorimetric analysis shows that the proportion and intensity of cells staining for ␣ 4 and ␤ 7 subunits are unaltered by adenosine treatment (data not shown). The time frame of the regulation of adhesion by adenosine is of the same order as the regulation of ␣ 4 -dependent binding of monocytes to VCAM-1 by CC chemokines [54] and the cytokine-regulated adhesiveness of leukemic cells through ␣ 4 integrin [55] . We suspect that ␣ 4 ␤ 7 function may be regulated by adenosine through protein kinase/phosphatase pathways. We have recently shown that the adhesion of T cells to MCA-38 cells is modulated by kinase pathways located predominantly within the effector cell [42] .
The inhibitory effect of adenosine in our adhesion assays is most marked using T cells that have been just briefly (2 h) activated with anti-CD3 mAb. With longer stimulation times (6 -48 h) using anti-CD3 the inhibition due to adenosine is of lesser magnitude (W. M. MacKenzie, D. W. Hoskin, and J. Blay, unpublished data). This again is consistent with the effect of adenosine being exerted through ␣ 4 ␤ 7 : more prolonged (Ͼ3-h) activation of human or mouse T cells with anti-CD3 mAbs leads to a downregulation of ␣ 4 chain expression accompanied by loss of the epitope recognized by the R1-2 mAb [56, 57] .
Adenosine suppression of T lymphocyte ␣ 4 ␤ 7 function may play a role in reducing T cell infiltration into (or retention within) solid tumors, which has been shown to involve interactions through ␣ 4 ␤ 7 [58] . Conversely, in T cell lymphomas, high concentrations of extracellular adenosine might restrain ␣ 4 ␤ 7 -dependent interactions but be lost at the tumor margin to allow ␣ 4 ␤ 7 -mediated cancer cell expansion. High expression of ␣ 4 ␤ 7 has been linked to the greater leukemogenicity of the NQ22 T cell lymphoma, which interestingly also induces upregulation of VCAM-1 on endothelial cells, promoting endothelial attachment and extravasation [59] . Cellular interactions through ␣ 4 ␤ 7 have also been postulated to play a role in leukocyte localization in inflammatory disorders such as asthma [23] , intestinal inflammation [60, 61] , and rheumatic disorders [62, 63] and may be subject to regulation by adenosine. Adenosine is known to have antiinflammatory properties in addition to its immunosuppressive effects [64] . The adenosine-dependent inhibition of adhesion through ␣ 4 ␤ 7 that we have identified in T cells may therefore be important in a variety of disease situations.
